214470-27-6

Basic information

• Product Name: 7-methoxy-6-nitro-4-oxo-1,4-dihydroquinoline-3-carbonitrile
• Synonyms: 4-Hydroxy-7-methoxy-6-nitrochinolin-3-carbonitril; 4-hydroxy-7-methoxy-6-nitroquinoline-3-carbonitrile; 7-Methoxy-6-nitro-4-oxo-1,4-dihydrochinolin-3-carbonitril
• CAS NO: 214470-27-6
• Molecular Formula: C₁₁H₇N₃O₄
• Molecular Weight: 245.191
• Mol File: 214470-27-6.mol

Chemical Properties

• Boiling Point: 450.829°C at 760 mmHg
• Flash Point: 226.453°C
• Density: 1.511g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.647
• CAS DataBase Reference: 7-methoxy-6-nitro-4-oxo-1,4-dihydroquinoline-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 7-methoxy-6-nitro-4-oxo-1,4-dihydroquinoline-3-carbonitrile(214470-27-6)
• EPA Substance Registry System: 7-methoxy-6-nitro-4-oxo-1,4-dihydroquinoline-3-carbonitrile(214470-27-6)

Safety Data

• Hazardous Substances Data: 214470-27-6(Hazardous Substances Data)

Upstream product

• 536-90-3 m-Anisidine 
• 71083-64-2 1,4-dihydro-7-methoxy-4-oxo-quinoline-3-carbonitrile 
• 7440-44-0 pyrographite 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 90564-41-3 2,4-dimethoxy-5-nitrobenzoic acid 
• 19861-62-2 2,4-dichloro-5-nitrobenzoic acid 
• 16292-88-9 3-methoxy-4-nitroanilin 
• 501684-26-0 (E)-2-Cyano-3-(3-methoxy-4-nitro-phenylamino)-acrylic acid ethyl ester 

Downstream Products

• 214485-59-3 4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-6-nitro-quinoline-3-carbonitrile 
• 214470-33-4 4-chloro-7-methoxy-6-nitro-quinoline-3-carbonitrile 
• 214485-60-6 6-amino-4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinoline-3-carbonitrile 
• 214484-01-2 4-[(3-bromophenyl)amino]-7-methoxy-6-nitro-quinoline-3-carbonitrile 
• 214484-03-4 6-amino-4-[(3-bromophenyl)amino]-7-methoxy-quinoline-3-carbonitrile 
• 214485-38-8 N-{4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl}-4-morpholino-2-butenamide 
• 501684-30-6 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-6-nitro-quinoline-3-carbonitrile 
• 501684-31-7 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile 
• 501684-29-3 4-(3-chloro-4-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-nitro-quinoline-3-carbonitrile 
• 501684-27-1 7-(3-chloro-propoxy)-4-hydroxy-6-nitroquinoline-3-carbonitrile 

Relevant articles and documents

4-quinazoline amine derivatives and their use

A 4-quinazoline amine derivative as represented by formula (1), a pharmaceutical composition comprising the derivative, and an application thereof in preparing medicine for curing cancer. The cancer is a drug-resistant cancer, preferably a cancer resisting an EGFR reversible inhibitor, and more preferably, a cancer resisting gefitinib, erlotinib or lapatinib; alternatively, the cancer carries EGFR mutation.

Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

This invention provides compounds of formula 1 wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.

SUBSTITUTED 3-CYANO QUINOLINES

This invention provides compounds having formula (1), wherein: X is cycloalkyl which may be optionally substituted; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally substituted; n is 0-1; Y is -NH-, -O-, -S-, or -NR-; R is alkyl of 1-6 carbon atoms; R1, R2, R3 and R4 are each, independently, hydrogen, halogen, alkyl, alkenyl, alkynyl, alkenyloxy, alkynyloxy, hydroxymethyl, halomethyl, alkanoyloxy, alkenoyloxy, alkynoyloxy, alkanoyloxymethyl, alkenoyloxymethyl, alkynoyloxymethyl, alkoxymethyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy, carboalkyl, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino, alkylamino, dialkylamino, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, phenylamino, benzylamino, formulae (a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q or r); R5 is alkyl which may be optionally substituted, or phenyl which may be optionally substituted; R6 is hydrogen, alkyl, or alkenyl; R7 is chloro or bromo; R8 is hydrogen, alkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-cycloalkylaminoalkyl, N-cycloalkyl-N-alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, morpholino-N-alkyl, piperidino-N-alkyl, N-alkyl-piperidino-N-alkyl, azacycloalkyl-N-alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, carboalkoxy, phenyl, carboalkyl +, chloro, fluoro, or bromo; Z is amino, hydroxy, alkoxy, alkylamino, dialkylamino, morpholino, piperazino, N-alkylpiperazino, or pyrrolidino; m = 1-4, q = 1-3, and p = 0-3; any of the substituents R1, R2, R3 or R4 that are located on contiguous carbon atoms can together be the divalent radical -O-C(R8)2-O-; or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R1, R2, R3 and R4 are hydrogen, and n is O, X is not 2-methylphenyl, which are inhibitors of protein tyrosine kinase.

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epi

A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared. These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Mic

Tricyclic protein kinase inhibitors

This invention provides compounds of Formula (I), where A″, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

TRICYCLIC PROTEIN KINASE INHIBITORS

This invention provides compounds of Formula (I), where A'', Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS

This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein:R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

The syntheses and biological evaluations of 4-anilinoquinoline-3-carbonitrile analogues of the three clinical lead 4-anilinoquinazolines Iressa, Tarceva, and CI-1033 are described. The EGFR and HER-2 kinase inhibitory activities and the cell growth inhibition of the two series are compared with each other and with the clinical lead EKB-569. Similar activities are observed between these two series.